Smoking is a leading global cause of disease and mortality 1 . We established the Oxford-GlaxoSmithKline study (Ox-GSK) to perform a genome-wide meta-analysis of SNP association with smoking-related behavioral traits. Our final data set included 41,150 individuals drawn from 20 disease, population and control cohorts. Our analysis confirmed an effect on smoking quantity at a locus on 15q25 (P = 9.45 × 10 −19 ) that includes CHRNA5, CHRNA3 and CHRNB4, three genes encoding neuronal nicotinic acetylcholine receptor subunits. We used data from the 1000 Genomes project to investigate the region using imputation, which allowed for analysis of virtually all common SNPs in the region and offered a fivefold increase in marker density over HapMap2 (ref. 2) as an imputation reference panel. Our fine-mapping approach identified a SNP showing the highest significance, rs55853698, located within the promoter region of CHRNA5. Conditional analysis also identified a secondary locus (rs6495308) in CHRNA3.
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Smoking is a leading global cause of disease and mortality 1 . We established the Oxford-GlaxoSmithKline study (Ox-GSK) to perform a genome-wide meta-analysis of SNP association with smoking-related behavioral traits. Our final data set included 41,150 individuals drawn from 20 disease, population and control cohorts. Our analysis confirmed an effect on smoking quantity at a locus on 15q25 (P = 9.45 × 10 −19 ) that includes CHRNA5, CHRNA3 and CHRNB4, three genes encoding neuronal nicotinic acetylcholine receptor subunits. We used data from the 1000 Genomes project to investigate the region using imputation, which allowed for analysis of virtually all common SNPs in the region and offered a fivefold increase in marker density over HapMap2 (ref. 2) as an imputation reference panel. Our fine-mapping approach identified a SNP showing the highest significance, rs55853698, located within the promoter region of CHRNA5. Conditional analysis also identified a secondary locus (rs6495308) in CHRNA3.
Smoking behavior and nicotine dependence are multifactorial traits with substantial genetic influences 3 . There is an urgent need to better understand the molecular neurobiology of nicotine dependence in order to design targeted, more effective therapies 4 . Recently, genome-wide association studies (GWAS) have established one locus associated with nicotine dependence and smoking quantity, which implicates a cluster of three genes, CHRNA5, CHRNA3 and CHRNB4 on chromosome 15q25, which encode neuronal nicotinic acetylcholine receptor subunits [5] [6] [7] [8] [9] . This locus is also associated with lung cancer 8, 10, 11 , peripheral arterial disease 8 and chronic obstructive pulmonary disease and lung function 12 .
We initially performed a GWAS meta-analytic study of smokingrelated traits in a total sample of 41,150 individuals of European descent, sourced from several disease, population and control cohorts ( Table 1, Supplementary Table 1 and Online Methods). As the cohorts were genotyped on a variety of different genome-wide SNP arrays ( Table 1 and Supplementary Table 1) , we first imputed genotypes for all data sets 13 for all SNPs in the HapMap version release 22 (ref. 2) .
The main focus of our analysis was on smoking quantity within current and past smokers, defined as a semiquantitative trait based on the self-reported variable of cigarettes smoked per day (CPD) 8 . We performed association analyses separately within each cohort under Meta-analysis and imputation refines the association of 15q25 with smoking quantity l e t t e r s an additive model using covariate effects for age, sex, disease case or control status where applicable, and other cohort-specific covariates (Supplementary Table 1) . A meta-analysis was then carried out by combining study-specific β (regression coefficient) estimates using a fixed effects model 14 . In total, 15,574 subjects reported CPD values over zero and were used for the meta-analysis of smoking quantity ( Table 1 and Supplementary Table 1) . We followed up our most promising association findings by comparing them with results from two concurrent GWAS meta-analyses of smoking: the ENGAGE study of 46,481 subjects 15 and the TAG study of 74,035 subjects 16 . We also made our meta-analysis results available to the authors of those studies to check their top findings for replication.
Our meta-analysis of smoking quantity identified the CHRNA5-CHRNA3 locus on 15q25 as the single significant locus of note in the genome (Fig. 1 , Table 2 and Supplementary Table 2) , with a minimum P = 9.45 × 10 −19 for rs1051730, a SNP which has been previously reported to be associated with traits related to smoking [5] [6] [7] [8] [9] ; we also found highly significant P values for many other SNPs in the region ( Supplementary Fig. 1 and Supplementary Table 2 ). All cohorts in the analysis contributed at least somewhat to the 15q25 association (Supplementary Fig. 1 ). Each copy of the A allele (34% frequency) had a quantitative effect size on smoking quantity of 0.079 (95% confidence interval 0.070-0.088), which is in line with previous estimates 8 . A joint analysis of our total data set, together with the TAG and ENGAGE data sets, for rs1051730 yielded P = 1.71 × 10 −66 ( Table 2) .
Multiple variants at the 15q25 locus have been suggested to underlie its effect on smoking quantity, including a nonsynonymous SNP in CHRNA5 and variants that affect mRNA expression levels [17] [18] [19] . We utilized our very large sample, in combination with data from the 1000 Genomes Project (see URLs), to perform fine mapping and modeling of the 15q25 locus in relation to smoking quantity. We reasoned that with the near complete information on common SNPs derived from the 1000 Genomes data set, it might be possible to pinpoint a variant or combination of variants that can explain the entirety of the signal of association at 15q25. We used data from 108 estimated CEU European-ancestry haplotypes from the April 2009 release of the 1000 Genomes Pilot 1 data. This data set contained 2,189 SNPs in our region of interest (Online Methods), which was approximately a fivefold increase in density compared to the 437 SNPs in release 22 of HapMap. By imputing genotypes for all SNPs across this locus from 1000 Genomes and by repeating the meta-analysis, we found that the most significant association was with a new and previously untested SNP which is not in the HapMap and is located within the 5′ untranslated region of CHRNA5; this location makes it a candidate for affecting mRNA transcription (rs55853698, P = 1.31 × 10 −16 ; Fig. 2 ). The P value for the commonly reported SNP rs1051730 in this Figure 1 Plot showing the significance of association of all SNPs in the genome-wide smoking quantity meta-analysis. SNPs are plotted on the x axis according to their positions on each chromosome against association with smoking quantity on the y axis (−log 10 P value). SNPs with P values < 1.0 × 10 −5 are highlighted in green.
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VOLUME 42 | NUMBER 5 | MAY 2010 Nature GeNetics l e t t e r s analysis was similar but slightly less significant (P = 1.47 × 10 −15 ). The P values for our 1000 Genomes analysis were generally higher than those from our HapMap-based analysis because not all of our study cohorts were included in the 1000 Genomes imputation (see Online Methods). rs55853698 is a G/T substitution, where the G allele has a frequency ranging from 0.313-0.378 across the various cohorts.
To investigate whether the association to smoking quantity at 15q25 can be explained completely by rs55853698, we carried out tests of association for all SNPs spanning the CHRNA5-CHRNA3 locus conditional upon this SNP (Fig. 2) . Residual association was still detected at many SNPs in the region, with the most significant signal occurring at rs6495308 (P = 3.96 × 10 −5 ), which is located within an intron of CHRNA3 (Fig. 2) . In the unconditioned analysis, rs6495308 has a significance of P = 3.30 × 10 −10 . Further conditioning on rs6495308 after conditioning on rs55853698 leaves no obvious signal of association in the region (Supplementary Fig. 2 ), suggesting that these two SNPs together could be sufficient to explain the genetic effect.
It has previously been suggested 18 that a nonsynonymous SNP, rs16969968, in CHRNA5 is associated with nicotine dependence risk and lung cancer risk, but also that variants that cause high expression of CHRNA5 mRNA, tagged by rs588765, increase the risk for nicotine dependence independently. The marginal P values of rs16969968 and rs588765 in our meta-analysis were P = 1.64 × 10 −18 and P = 1.74 × 10 −3 . Conditional analysis on rs16969968 within our cohorts still left residual association within the region (Supplementary Fig. 2) , with the most significant signal again occurring at rs6495308 (P = 1.54 × 10 −5 ). Conditioning on both rs16969968 and rs588765, that is, the combination previously proposed 18 , leaves no obvious signal of association (Supplementary Fig. 2) . To further investigate which pair of SNPs best explains the signal of association, we used the Bayesian information criteria (BIC) measure of model fit, in which smaller values indicate a better fit 20 . For the previous model 18 , that is, conditioning on both rs16969968 and rs588765, we obtained BIC = 22,719.87 and a posterior probability 0.15. For the model conditioning on the new promoter SNP rs55853698 and rs6495308, we obtained BIC = 22,716.49 and a posterior probability 0.85, which indicates a better model fit.
Examination of the linkage disequilibrium (LD) structure between the SNPs considered here shows that rs1051730, rs16969968 and rs55853698 are all close-tagging proxies of each other (all pairwise r 2 > 0.96). These variants either tag or potentially cause the principal risk for high smoking quantity attributable to the 15q25 locus, but the high LD makes it difficult to assign specific causality. The SNPs that show residual association, rs588765 and rs6495308, are in low LD with each other (r 2 = 0.21) and are both in only modest LD with the principal SNPs (maximum r 2 = 0.47). It is not therefore clear that this locus can be completely understood in the way previously proposed 18 . Although the nonsynonymous SNP in CHRNA5, rs16969968, may be important, we have identified a new and potentially functional SNP in the 5′ untranslated region of this gene that is a close proxy for the nonsynonymous SNP in terms of LD, but which shows a slightly more significant association in our metaanalysis. Furthermore, although rs588765 can explain much of the secondary or residual association at this locus, we find that a largely independent variant within CHRNA3, rs6495308, is the best tagger of the residually associated variation; this variant also contributes to a better-fitting two-SNP model and has a much stronger marginal significance in our unconditioned analysis (P = 3.30 × 10 −10 for rs6495308 as compared to P = 1.74 × 10 −3 for rs588765).
To our knowledge, our analysis has, for the first time, surveyed virtually all of the common SNPs in the 15q25 region and provides 
l e t t e r s
one of the first examples of how data from the 1000 Genomes Project can contribute new information to mapping and characterizing loci for complex traits. We recommend that further analysis of this locus should not be limited in focus to CHRNA5, nor particularly to the nonsynonymous SNP rs16969968. It is notoriously difficult to distinguish functional variation when there is high LD across a region 21 . There are many ways in which variants can be functional, including expression regulatory changes that affect either close or distant genes, epigenetic changes, splicing effects, alterations to microRNA binding sites, or noncoding RNAs 21 . It is also conceivable that association with common variants can arise through the effects of multiple, rarer variants that happen to be relatively restricted to specific haplotype backgrounds. In addition, common insertions or deletions can have functional effects, and the 1000 Genomes data will allow for analysis of this class of variant via an imputation framework. The second-strongest association with smoking quantity within the genome in our meta-analysis was at a locus on 8p21 that received modest support from the TAG and ENGAGE studies (Supplementary Table 2 and Supplementary Fig. 3 ; P = 5.26 × 10 −7 for rs11782673). This locus would not remain significant after correcting for genome-wide multiple testing; however, it is noteworthy that the locus spans CHRNA2, another gene that encodes a neuronal nicotinic acetylcholine receptor subunit.
In addition to our analysis of smoking quantity, we also performed a genome-wide test for allelic differences between those who reported currently smoking or having smoked in the past versus those who said they had never been smokers (the ever/never phenotype; sample sizes are shown in Table 1 and Supplementary Table 1 ). This test aimed to identify genetic effects on the establishment of a smoking habit. No locus achieved genome-wide significance in this analysis, and none of the top 15 loci showed evidence of replication (Supplementary Table 2 and Supplementary Fig. 4) . Likewise, no consistent results emerged when we tested for allelic differences between those who reported smoking at present versus those who had smoked in the past but had stopped at the time of interview (Supplementary Table 2 and Supplementary Fig. 4) . When age-adjusted, this is a rough measure of smoking cessation.
Our study identified association at some loci that, although not reaching genome-wide significance in our own meta-analysis, supported findings from the concurrent TAG and ENGAGE studies 15, 16 . These include new loci on chromosomes 8 and 19 for smoking quantity, on chromosome 11 for ever/never and on chromosome 9 for current versus non-current smokers 15, 16 . These findings have provided further new insights into the biology of smoking behavior. 
MetHOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINe MetHOdS
Study samples. Study collections and their basic characteristics are listed in
GEMS 22 : The Genetic Epidemiology of Metabolic Syndrome (GEMS) study consists of dyslipidemic case individuals (age 20-65 years) matched with normolipidemic controls by sex and recruitment site, drawn from non-Mediterranean subjects of the GEMS study (from Finland, Switzerland, Canada, Australia and the United States).
CoLaus 23 : The Cohorte Lausannoise (CoLaus) is a single-center, cross-sectional population-based study, including individuals aged 35-75 years randomly selected from the list of residents of the city of Lausanne, Switzerland.
GSK COPD 12 : This collection includes case individuals with chronic obstructive pulmonary disease, diagnosed according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and unaffected controls recruited from Bergen, Norway.
GSK UPD 24 : This collection includes case individuals with recurrent major depression according to DSM-IV criteria and age-and gendermatched unaffected controls, recruited at the Max-Planck Institute of Psychiatry in Munich, Germany. Subjects were also recruited at two satellite recruiting hospitals (Bezirkskrankenhaus Augsburg and Klinikum Ingolstadt) in the Munich area.
GSK Bipolar 25 : The Bipolar collection included DSM-IV-diagnosed bipolar case individuals and controls from subjects recruited at three study sites: the Institute of Psychiatry (IOP) in London, UK; the Centre for Addiction and Mental Health in Toronto, Canada; and the University of Dundee, UK.
GSK LOLIPOP 26 : The London Life Sciences Prospective Population (LOLIPOP) was a population based study including Indian Asian and European white men and women recruited from the lists of 58 general practitioners in West London.
GSK MedStar 27 : The MedStar cohort included case individuals with acute coronary syndrome or chronic coronary artery disease (CAD) from Washington DC, together with unaffected controls.
Penn-CATH 27 : The Penn-CATH cohort was a University of Pennsylvania Medical Center-based angiographic study from which case individuals with CAD and controls with no evidence of CAD at the coronary angiography were derived.
EPIC 28 : The EPIC-Obesity cohort was a case-control cohort for obesity drawn from the EPIC-Norfolk cohort which included men and women of European ancestry aged 39-79 years recruited in Norfolk, UK.
KORA 29 : The Cooperative Health Research in the Region of Augsburg (KORA) study was an epidemiological survey of the general population living in the city of Augsburg, southern Germany, and two adjacent counties.
WTCCC HT 30 : The WTCCC-HT collection comprised severely hypertensive probands ascertained from families with multiple affected members in the UK as part of the BRIGHT study.
WTCCC CAD, WTCCC CD and WTCCC RA 30 : These studies included individuals with CAD, Crohn's disease and rheumatoid arthritis from the Wellcome Trust Case Control Consortium Study.
POPGEN study 31 : The Population Genetic Cohort (POPGEN) was a cross sectional epidemiological survey of regional German populations from Schleswig-Holstein, northern Germany.
SHIP study 32 : The Study of Health in Pomerania (SHIP) was a longitudinal, population-based survey from West Pomerania, Germany. Data from the baseline cohort were used for this study.
VIS study 33 : This population cohort comprised Croatians aged 18-93 years recruited from the villages of Vis and Komiza on the Dalmatian island of Vis.
ORCADES study 34 : The Orkney Complex Disease Study (ORCADES) was a family-based, cross-sectional study that sought to identify genetic factors influencing cardiovascular and other disease risk in the population isolate of the Orkney Isles in northern Scotland.
KORCULA study 35 : The KORCULA study included healthy volunteers aged 18 and over from the villages of Lumbarda, Žrnovo, and Račišće on the Island of Korcula, Croatia.
SardiNIA study 36 : The SardiNIA was a population-based longitudinal cohort study that included male and female related individuals, aged 14 years and above, from a cluster of four towns in the Ogliastra province of Sardinia, Italy.
Genotyping, quality control and imputation. Supplementary Table 1 lists the various genotype platforms used for each cohort, the genotype calling algorithms, SNP and sample quality control measures and details of the imputation and association analysis software used. The quality control measures from previous analyses of each cohort were adopted for this study and are detailed in the table. We used NCBI build 36 coordinates for SNP base-pair positions so that all the cohorts could be successfully combined.
We imputed all SNPs reported in the CEU sample in HapMap Phase II using various imputation algorithms 13, 37 (see URLs for a link to ProbABEL). Imputations were performed after excluding samples and SNPs that did not meet the study-specific quality control criteria. Genotypes were imputed for SNPs not present in the genome-wide arrays or for those where genotyping had failed to meet the quality control criteria.
Only imputed SNPs with good imputation quality were included in the meta-analysis. This was defined as proper_info ≥ 0.5 (a software-specific statistic for the studies analyzed with IMPUTE/SNPTEST 13 ) or rsq-hat ≥ 0.5 (a statistic used for studies analyzed using MACH 37 ) and Imp_info ≥ 0.5 (a statistic used for studies analyzed using ProbABEL).
Derivation of smoking phenotypes. We used the categorical smoking quantity levels previously defined 8 . The smoking quantity levels were 0 (defined as 1-10 CPD), 1 (11-20 CPD), 2 (21-30 CPD) and 3 (31 or more CPD). Each increment represents an increase in smoking quantity of 10 cigarettes per day. Most of the cohorts in our study have maximal CPD recorded on each sample, but a few collected average CPD (Supplementary Table 1) . We examined the distributions of CPD across cohorts and found no large differences between those cohorts using average CPD and those using maximal CPD. The mean and standard deviation of the CPD measurements in each cohort are given in Supplementary Table 1 . The ever/never and current/non-current phenotypes used were those collected by the individual cohorts. Not all cohorts had all three phenotypes (smoking quantity, ever/never and current/non-current) collected. Precise details of the phenotypes collected in each cohort are given in Supplementary Table 1 . An assessment would typically be questionnairebased, following a structure such as the following:
Tick the option that best describes you: -I smoke now -I don't smoke now. I have stopped for … years. -I have never smoked About how many cigarettes do you or did you smoke per day? List the number of years you have smoked.
Statistical analysis and meta-analysis. Each cohort was analyzed separately for each of the three phenotypes considered. The majority of the analysis was carried out on the raw genotype data at the Department of Statistics, University of Oxford, but some cohorts (SardiNIA, VIS, KORCULA, ORCADES and SHIP) carried out their own analysis and submitted results for the meta-analysis. For the binary traits (ever/never and current/non-current) tests for additive genetic effects on the log-odds scale were carried out using logistic regression. For the categorical smoking quantity phenotype, tests for additive genetic effects were carried out on a linear scale using linear regression. The programs SNPTEST, ProbABEL and MERLIN were used on the various cohorts to fit these models, taking account of the genotype uncertainty at imputed SNPs. All tests conditioned on sex and age, and for some cohorts, other covariates of self-reported ancestry, country of origin or principal components analysisderived covariates were included (a complete list of covariates is given in Supplementary Table 1) . A genomic control inflation factor (λ) estimate was calculated for each phenotype and each cohort (Supplementary Table 3) .
The meta-analysis was carried out by combining study-specific β estimates using a fixed effects model 14, which used the inverse of the variance of the study-specific β estimates to give weight to the contribution of each study. The variance of each cohort's β estimate was multiplied by the genomic control λ estimate to correct for observed inflation 38 
